Clinical Trials Browser

Interventional × Carcinoma, Hepatocellular × Ipilimumab × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT07291076 2026-05-14

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Phase 1/2 Recruiting

129 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07166406 2026-05-04

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Phase 3 Recruiting

226 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04472767 2026-04-30

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Phase 2 Recruiting

35 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07075120 2026-04-30

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Phase 1 Recruiting

15 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07227012 2026-04-20

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Phase 1/2 Recruiting

138 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1/2 Recruiting

126 enrolled

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT07176650 2026-03-16

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Phase 1 Recruiting

246 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05665348 2026-03-09

TRIPLET

Phase 2/3 Completed

229 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

657 enrolled 57 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05220722 2025-10-23

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Phase 1/2 Terminated

23 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT05199285 2025-10-03

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Phase 2 Terminated

15 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Phase 1/2 Completed

145 enrolled 47 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05909995 2025-02-18

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Phase 1 Terminated

8 enrolled

DermatologicGastrointestinalGenitourinary

Turcot syndrome, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT05302921 2025-01-01

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Phase 2 Completed

5 enrolled

CNSDermatologicGastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Melanoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT04823403 2024-07-26

HIPANIV

Phase 1 Recruiting

27 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Phase 2 Recruiting

90 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03510871 2024-07-08

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Phase 2 Completed

43 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03752398 2024-07-05

DUET-3

Phase 1 Completed

198 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03222076 2023-07-10

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

Phase 2 Completed

30 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03682276 2022-12-13

PRIME-HCC

Phase 1/2 Unknown

32 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Phase 1/2 Completed

52 enrolled 25 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03203304 2021-06-10

Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer

Phase 1 Terminated

14 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

Clinical Trials

STELLAR-002

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

CheckMate 9DW

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

TRIPLET

CheckMate040

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

HIPANIV

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

DUET-3

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

PRIME-HCC

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer